<DOC>
	<DOCNO>NCT01884480</DOCNO>
	<brief_summary>In Kidney transplant recipient Once daily Tacrolimus poteb ] ntial advantage well adnerence , perhpas improvement reanl function compred twice daily tacrolimus formulation . Our center large experience North America once-daily tacrolimus ( advagraf ) Renal transplant recipient . Recently convert ~500 stable patient twice daily once-daily tacrolimus . We interest : 1. change renal function 2. dose change base ethnic diveristy 3. dose change base pharmacogenetics This helpnus understand good way utilize anti-rejection medication</brief_summary>
	<brief_title>Renal Function Pharmacogenetics Renal Transplant Recipients Converted From Tac BID Tac OD</brief_title>
	<detailed_description>The Renal transplant program St. Michael 's one large Canada . The CNI choice since 2000 tacrolimus base therapy . In 2009 program decide switch bid prograf daily advagraf de-novo renal transplant recipient ( RTR ) . Our Advagraf experience currently large North America . Because concern regard generic prograf , begin conversion &gt; 600 prevalent transplant patient bid prograf OD advagraf January 2012 . At present nearly complete . It recognize dose tacrolimus highly dependent pharmacogenentic difference relate CYP3A5 genotype . CYP3A % *3 ( nonexpressors ) require significantly high dos tacrolimus CYP3A5*1 ( expressers ) heterozygotes somewhere middle . Our study examine demographic , renal function tacrolimus dose Co level , pre post conversion tac BID , tac OD cohort convert patient . Of More scientific interest , retrospectively determine CYP3A5 genotype recipient require significant dose adjustment tac OD follow conversion compare match cohort recipient dose adjustment need . The hypothesis recipient require dose increase convert BID OD formulation , different CYP3A5 genotype tend towards CYP3A5*3 . This large cohort look question . Specifically may lead good dose tac OD , pre-emptive genotyping prior transplantation employ .</detailed_description>
	<criteria>Renal transplamnt recipient prograf convert advagraf</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Advagraf , pharmacogenetics , Cyp3A5</keyword>
</DOC>